Netupitant
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Netupitant |
| DrugBank ID | DB09048 |
| Brand Names (EU) | Netupitant |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.35% |
Approved Indication (EMA)
Akynzeo is indicated in adults for the: Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy. Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | nephrogenic syndrome of inappropriate antidiuresis | 98.35% | DL |
| 2 | leprosy | 98.25% | DL |
| 3 | migraine disorder | 97.49% | DL |
| 4 | migraine with or without aura, susceptibility to | 97.27% | DL |
| 5 | pulmonary hypertension | 97.22% | DL |
| 6 | migraine with brainstem aura | 97.14% | DL |
| 7 | kyphoscoliotic heart disease | 96.96% | DL |
| 8 | hyperargininemia | 96.57% | DL |
| 9 | coronary artery disease | 96.39% | DL |
| 10 | hypertrichosis (disease) | 96.30% | DL |
| 11 | malformation syndrome with odontal and/or periodontal component | 95.81% | DL |
| 12 | anomalous left coronary artery from the pulmonary artery | 95.80% | DL |
| 13 | Ambras type hypertrichosis universalis congenita | 95.75% | DL |
| 14 | syndrome with a Dandy-Walker malformation as major feature | 95.73% | DL |
| 15 | isolated genetic hair shaft abnormality | 95.56% | DL |
| 16 | myocardial ischemia | 95.11% | DL |
| 17 | atrophoderma vermiculata | 94.86% | DL |
| 18 | persistent Mullerian duct syndrome | 94.21% | DL |
| 19 | ulerythema ophryogenesis | 93.95% | DL |
| 20 | genetic multiple congenital anomalies/dysmorphic syndrome without intellectual disability | 93.74% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.